Kezar Life Sciences, Inc. (NASDAQ: KZR) reported Q3 EPS of ($2.78), $2.46 worse than the analyst estimate of ($0.32).

For earnings history and earnings-related data on Kezar Life Sciences, Inc. (KZR) click here.